Specialty pharmaceutical company focused on the treatment of gastrointestinal disorders
Location: Canada, Quebec, Quebec City
Investors 1
| Date | Name | Website |
| - | Aisling Ca... | aislingcap... |
Mentions in press and media 6
| Date | Title | Description |
| 05.02.2015 | AstraZeneca to acquire rights to Actavis’ branded respiratory portfolio in the US and Canada | AstraZeneca to acquire rights to Actavis’ branded respiratory portfolio in the US and Canada 05-02-2015 A new agreement strengthens AstraZeneca’s aclidinium respiratory franchise and adds immediate revenues with long-term growth potential. ... |
| 24.05.2013 | East Coast Life Sciences Roundup: Regeneron, Actavis, NPS, & More | Share Share on Facebook Share on Twitter LinkedIn Email Reprints Broad startup initiatives, big acquisitions, critical data readouts, and more characterized the news flowing out of the biotech sector along the East Coast this week. Details ... |
| 24.07.2012 | Chronic pain drug developer for cancer, lower back pain raises $3M | Location: Blue Bell, Pennsylvania Industry: Pharmaceuticals Solution/product: Its lead product is chronic pain treatment LevoCap, a proprietary once-a-day extended release dosage form of the opioid levorphanol. It is being presented as an a... |
| 02.06.2011 | Alzheimer’s disease drug Aricept faces rising tide of generic competitors | Aricept’s patents expired last November and the first drugs company to market an Aricept generic was Ranbaxy, which had 180 days of marketing exclusivity. With those six months passed, generics competitors are now aggressively rolling out t... |
| - | Chronic pain drug developer for cancer, lower back pain raises $3M | Company name: Relmada Therapeutics Location: Blue Bell, Pennsylvania Industry: Pharmaceuticals Solution/product: Its lead product is chronic pain treatment LevoCap, a proprietary once-a-day extended release dosage form of the opioid levorph... |
| - | Alzheimer’s disease drug Aricept faces rising tide of generic competitors | The patent wall protecting Eisai‘s (TYO:4523) blockbuster Alzheimer’s disease drug Aricept is crumbling fast with two more generics companies receiving U.S. Food and Drug Administration approval this week to take on the drug that Eisai manu... |